| 0.9772 -0.013 (-1.3%) | 10-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.46 | 1-year : | 1.68 |
| Resists | First : | 1.25 | Second : | 1.44 |
| Pivot price | 1.1  |
|||
| Supports | First : | 0.94 | Second : | 0.78 |
| MAs | MA(5) : | 1.01 |
MA(20) : | 1.15 |
| MA(100) : | 1.45 |
MA(250) : | 2.24 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 14.3 |
| RSI | RSI(14): 30.1 |
|||
| 52-week | High : | 4.98 | Low : | 0.94 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NCNA ] has closed above bottom band by 15.9%. Bollinger Bands are 4.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1 - 1.01 | 1.01 - 1.01 |
| Low: | 0.96 - 0.97 | 0.97 - 0.98 |
| Close: | 0.97 - 0.98 | 0.98 - 0.99 |
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Fri, 16 Oct 2026
Nucana Stock Price Forecast. Should You Buy NCNA? - StockInvest.us
Thu, 15 Oct 2026
NuCana won a European patent: what it means for NuCana stock - ad-hoc-news.de
Tue, 06 Oct 2026
NuCana stock gained 2.83 percent on October 6 as patent coverage expands - ad-hoc-news.de
Mon, 05 Oct 2026
NuCana plc (NCNA) Slips 2.75% to $1.06 as Micro-Cap Biotech Tests Range Support - Earnings Quality Factor - https://www.siam.in/
Wed, 30 Sep 2026
NuCana (NCNA) Secures Key European Patent for NUC-7738 Anti-Canc - GuruFocus
Wed, 30 Sep 2026
A cancer-treatment candidate has over 85 issued patents worldwide. NuCana gained another in Europe. - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.5 (%) |
| Shares Short | 100 (K) |
| Shares Short P.Month | 159 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.32 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -43.5 % |
| Return on Equity (ttm) | -70.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.15 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|